Drugs / Tavokinogene Telseplasmid
Tavokinogene Telseplasmid
also known as
TAVO · 12-NGVL331 · Dna plasmid encoding interleukin-12 ino-9012 · Immunopulse il-12 · PNGVL3-HIL-12 · pUMVC3-hIL · TAVO-EP · Tavokinogen telseplasmido · +1 more
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04627675 | Dec 2020 → Sep 2022 | COVID-19 | Providence Health & Services | Terminated | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT04526730 | Dec 2020 → Mar 2024 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03823131 | May 2019 → Jul 2022 | head and neck squamous cell carcinoma | Chase Heaton, MD | Terminated | No outcome recorded |
| Phase 2 | NCT03567720 | Oct 2018 → Apr 2024 | triple-negative breast carcinoma | OncoSec Medical Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT03132675 | Oct 2017 → Mar 2023 | melanoma | OncoSec Medical Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT02345330 | May 2015 → Nov 2016 | head and neck squamous cell carcinoma | OncoSec Medical Incorporated | Terminated | No outcome recorded |
| Phase 2 | NCT01579318 | Jun 2012 → Jun 2014 | mycosis fungoides | OncoSec Medical Incorporated | Terminated | No outcome recorded |
| Phase 2 | NCT01502293 | Feb 2012 → Mar 2016 | melanoma | OncoSec Medical Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT01440816 | Jan 2012 → Apr 2015 | cutaneous neuroendocrine carcinoma | OncoSec Medical Incorporated | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tavokinogene Telseplasmid | “IL-12p70 plasmid DNA electroporation (tavokinogene telseplasmid) has been extensively studied in over 209 subjects across 11 trials including later stage human cancer trials...” NCT04627675 ↗8“Intratumoral tavokinogene telseplasmid delivered by electroporation (TAVO-EP) results in localized expression of IL-12 within the tumor microenvironment (TME).” PMID 39417680 ↗ Dec 2024 |
| Known as | 12-NGVL331 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Known as | Dna plasmid encoding interleukin-12 ino-9012 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Known as | Immunopulse il-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Known as | PNGVL3-HIL-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Known as | pUMVC3-hIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Known as | TAVO | “Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP) in combination with pembrolizumab therapy.” NCT03567720 ↗2“Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab.” NCT03132675 ↗ “Tavokinogene Telseplasmid (tavo)” NCT01502293 ↗ |
| Known as | TAVO-EP | “Intratumoral tavokinogene telseplasmid delivered by electroporation (TAVO-EP) results in localized expression of IL-12 within the tumor microenvironment (TME).” PMID 39417680 ↗ Dec 2024 |
| Known as | Tavokinogen telseplasmido | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Known as | Tavokinogene telseplasmide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298206 ↗ |
| Modality | Vaccine | “in vivo electroporation-mediated plasmid DNA vaccine therapy” NCT01440816 ↗ |
| Route | Other | “Patients received intratumoral injection(s) of tavo.” NCT01502293 ↗ |